Answers are grounded in this paper and cite their sources.
Real-world outcomes show similarities in nonsmall cell lung cancer patients receiving neoadjuvant therapy, suggesting need for careful evaluation.
Real‐world outcomes for patients with nonsmall cell lung cancer who receive neoadjuvant therapy are similar to the outcomes of those who received treatment on neoadjuvant and perioperative nonsmall cell lung cancer trials. Careful patient selection and presurgical evaluation is important for ensuring patients are able to complete neoadjuvant therapy and undergo surgery.
No takes yet. Share an insight, caveat, or question.
Cittolin‐Santos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: